Skip to content

Prevalence and risk factors of residual dizziness after successful repositioning treatment in benign paroxysmal positional vertigo: a nested case-control study

Prevalence and risk factors of resudual dizziness after successful repositioning treatment in benign paroxysmal positional vertigo: a nested case-control study

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000036131
Enrollment
Unknown
Registered
2020-08-21
Start date
2020-09-01
Completion date
Unknown
Last updated
2020-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

benign paroxysmal positional vertigo

Interventions

BPPV patients without RD:Nil
BPPV patients with RD:Nil
BPPV:Nil

Sponsors

Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria for benign paroxysmal positional vertigo in the Guidelines for the Diagnosis and Treatment of Benign Paroxysmal Positional Vertigo (2017), and the type of nystagmus meets the performance of the involved semicircular canal (posterior semicircular canal or horizontal semicircular canal, benign paroxysmal position Sexual vertigo); (2) The repositioning treatment was successful on the day of treatment, and the repeated provocative test was negative; (3) Age 20-80 years old; (4) Patients and their families informed consent.

Exclusion criteria

Exclusion criteria: (1) Previously suffering from deafness, Meniere's disease, vestibular neuritis, severely restricted neck movement, vestibular migraine, severe brain injury, cerebrovascular disease, epilepsy, drug dependence, schizophrenia and other serious mental diseases and organs History of insufficiency; (2) Cranial CT/MRI indicates posterior fossa disease; (3) Benign paroxysmal positional vertigo patients with multiple tube involvement.

Design outcomes

Primary

MeasureTime frame
baseline demographic Data;baseline clinical Data;Dizziness Handicap Inventory (baseline, week 1, week 4);Vertigo Visual Analog Scale(baseline, week 1, 2, 3, 4);Hospital Anxiety and Depression Scale(baseline, week 4);Vestibular Evoked Myogenic Potential;Multimodal Magnetic Resonance;

Countries

China

Contacts

Public ContactWei Chen

Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine

david_chen8106@hotmail.com+86 13774421505

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026